Protagonist Therapeutics, Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Protagonist Therapeutics, Inc (PTGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $32.48 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-25
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $10.05, a 55.45% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $22.56, a 30.48% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $17.29, a 245.11% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $5.01, a 6.60% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $32.48, a 61.83% increase from fiscal 2024.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $20.07, a 85.66% increase from fiscal 2023.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $10.81, a 38.30% decline from fiscal 2022.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $17.52, a 20.15% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $32.48 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $20.07 10-K · filed 2026-02-25 | |||
| 2023-12-31 | $10.81 10-K · filed 2026-02-25 | |||
| 2023-06-30 | $10.40 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $10.05 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $17.52 10-K · filed 2025-02-21 | |||
| 2022-09-30 | $18.67 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $19.92 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $22.56 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $21.94 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $21.92 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $19.79 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $17.29 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $7.76 10-K · filed 2023-03-15 | |||
| 2020-09-30 | $6.82 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $5.46 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $5.01 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $5.45 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $5.42 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $5.13 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $4.70 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $8.12 10-K · filed 2021-03-10 | |||
| 2018-09-30 | $8.35 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $9.16 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $10.51 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $7.74 10-K · filed 2020-03-10 | |||
| 2017-09-30 | $7.11 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $6.26 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $7.57 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $8.20 10-K · filed 2017-03-07 | |||
| 2016-09-30 | $6.09 10-Q · filed 2016-11-14 | $3.16 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | $2.27 10-Q · filed 2016-09-15 | |||
| 2016-03-31 | $0.68 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $0.69 10-K · filed 2017-03-07 | |||
| 2015-09-30 | $1.04 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | $1.04 10-Q · filed 2016-09-15 | |||
| 2014-12-31 | $0.82 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |